Target therapy in metastatic renal cell carcinoma
Giacomo Cartenì(Ospedale Antonio Cardarelli), N. Panza, M. Biglietto(Ospedale Antonio Cardarelli), Bruno Chiurazzi(Ospedale Antonio Cardarelli), Pasquale De Rosa, G.P. Nicolella(Radiation Oncology Institute), Antonio Maria Grimaldi(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Manuela Otero(Ospedale Antonio Cardarelli), Giovanni Esposito(Johannes Gutenberg University Mainz), Teresa Guida(Institute for Experimental Endocrinology and Oncology), Roberto Fiorentino(Ospedale Antonio Cardarelli), Ferdinando Riccardi(Ospedale Antonio Cardarelli), E. Perrotta(Ospedale Antonio Cardarelli), C Battista(Ospedale Antonio Cardarelli)
Cited by 2
Related Papers
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
|Clinical Cancer Research|2019|240
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
|Journal of Clinical Oncology|2022|231
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis
|Annals of Oncology|2009|205